Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol
Status:
COMPLETED
Trial end date:
2025-03-26
Target enrollment:
Participant gender:
Summary
PARADIGM (Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol) is a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial to assess the safety and efficacy of solriamfetol for the treatment of major depressive disorder (MDD) in adults.